BIOMARKER:

HRAS G13R

Entrez ID:

Related biomarkers:

‹

›

HRAS G13R HRAS G13R	Urothelial Cancer Urothelial Cancer	tipifarnib Sensitive: C3 – Early Trials
HRAS G13R HRAS G13R	Squamous Cell Carcinoma of Head and Neck SCCHN	tipifarnib Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	FRAX597 Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib + dasatinib Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	trametinib Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	dasatinib + SCH772984 Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	dasatinib + selumetinib Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	selumetinib Sensitive: D – Preclinical
HRAS G13R HRAS G13R	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	CI-1040 Sensitive: D – Preclinical

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

Associations